- 24.2k views
CAR T Cells in Cancer Gene Therapy
CAR T-cell therapy is a groundbreaking approach in cancer gene therapy that harnesses a patient’s immune cells to target and destroy cancer cells. In this technique, T-cells are genetically modified to express chimeric antigen receptors (CARs) that specifically recognize cancer cells. Once reintroduced into the patient, these CAR T-cells seek out and eliminate cancer cells with high precision. This therapy has shown remarkable success in treating certain types of blood cancers, such as leukemia and lymphoma, and is being explored for solid tumors. CAR T-cell therapy offers a promising personalized treatment, with ongoing research aimed at enhancing its safety, effectiveness, and applicability to a wider range of cancers.
About the Speaker
Dr. Shibichakravarthy Kannan
Consultant Medical Genetics, Apollo Health and Lifestyle Limited, Hyderabad
Dr. Shibichakravarthy Kannan, MBBS, PhD is a Founder & CEO at Theranosis Life Sciences Pvt Ltd. He is a Physician Scientist from Chennai, India - trained in the USA . He has 15 years of clinical & translational research experience including 3 years of Industry experience in the areas - Bioinformatics, Next Generation Sequencing, Scientific communications at Novartis, Drug Discovery & Development, Clinical Genetics & tumor immunotherapy. Dr Kannan’s research focuses on Tumor Immunology & Immunotherapy. He has more than 20 research publications in high impact peer reviewed medical journals. He is Biobanking Expertise – Founded the Lymphoma Tissue Biobank at MD Anderson; replicating this model in Hyderabad & Bangalore, India and Circulating Tumor Cells – developing a platform for performing liquid biopsy of most common solid tumors such as breast, lung, prostate and colorectal cancer.
Upcoming Case Discussions
Gynaecologist’s Guide to Ovarian Cancer
Join us for a special webinar on World Ovarian Cancer Day, titled "Gynaecologist’s Guide to Ovarian Cancer." This expert-led session will delve into the latest advancements in early diagnosis, risk stratification, and evidence-based management of ovarian cancer. Tailored for gynecologists and healthcare professionals, the session will also explore real-world case discussions and multidisciplinary treatment approaches. Let’s come together to raise awareness and empower clinicians in the fight against this silent but deadly disease
Massive Transfusion Protocol
Massive Transfusion Protocol (MTP) is a standardized medical procedure activated in cases of severe hemorrhage, typically involving the rapid administration of large volumes of blood products. The goal is to restore circulating volume, maintain hemostasis, and prevent the lethal triad of hypothermia, acidosis, and coagulopathy. MTP usually involves a balanced ratio of packed red blood cells, plasma, and platelets, often in a 1:1:1 ratio. Early activation and coordination among trauma teams, laboratory services, and blood banks are essential for its success.
Sleep Apnea and Daytime Fatigue
Sleep Disorder Breathing is a term for a group of conditions with abnormal breathing patterns during sleep. This affects everyday functioning and well being.There are few types of SDB which include upper airways resistance, hypopnea, apnea, catathrenia and heavy snoring. People suffering with SDB can have daytime symptoms that result in poor sleep also. There can also be sleepiness, depressed mood, irritability and cognitive dysfunction.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr. Shibichakravarthy Kannan's Talks on Assimilate
- 12th -Nov -2024, TIME : 3:00PM TO 4:00 PM
- 0
CAR T-cell therapy is a groundbreaking approach in cancer gene therapy that harnesses a patient’s immune cells to target and destroy cancer cells. In this technique, T-cells are genetically modified to express chimeric antigen receptors (CARs) that specifically recognize cancer cells. Once reintroduced into the patient, these CAR T-cells seek out and eliminate cancer cells with high precision. This therapy has shown remarkable success in treating certain types of blood cancers, such as leukemia and lymphoma, and is being explored for solid tumors. CAR T-cell therapy offers a promising personalized treatment, with ongoing research aimed at enhancing its safety, effectiveness, and applicability to a wider range of cancers.
- 12th -Nov -2024, TIME : 3:00PM TO 4:00 PM
- 0
CAR T-cell therapy is a groundbreaking approach in cancer gene therapy that harnesses a patient’s immune cells to target and destroy cancer cells. In this technique, T-cells are genetically modified to express chimeric antigen receptors (CARs) that specifically recognize cancer cells. Once reintroduced into the patient, these CAR T-cells seek out and eliminate cancer cells with high precision. This therapy has shown remarkable success in treating certain types of blood cancers, such as leukemia and lymphoma, and is being explored for solid tumors. CAR T-cell therapy offers a promising personalized treatment, with ongoing research aimed at enhancing its safety, effectiveness, and applicability to a wider range of cancers.
- 12th -Nov -2024, TIME : 3:00PM TO 4:00 PM
- 0
CAR T-cell therapy is a groundbreaking approach in cancer gene therapy that harnesses a patient’s immune cells to target and destroy cancer cells. In this technique, T-cells are genetically modified to express chimeric antigen receptors (CARs) that specifically recognize cancer cells. Once reintroduced into the patient, these CAR T-cells seek out and eliminate cancer cells with high precision. This therapy has shown remarkable success in treating certain types of blood cancers, such as leukemia and lymphoma, and is being explored for solid tumors. CAR T-cell therapy offers a promising personalized treatment, with ongoing research aimed at enhancing its safety, effectiveness, and applicability to a wider range of cancers.
- 12th -Nov -2024, TIME : 3:00PM TO 4:00 PM
- 0
CAR T-cell therapy is a groundbreaking approach in cancer gene therapy that harnesses a patient’s immune cells to target and destroy cancer cells. In this technique, T-cells are genetically modified to express chimeric antigen receptors (CARs) that specifically recognize cancer cells. Once reintroduced into the patient, these CAR T-cells seek out and eliminate cancer cells with high precision. This therapy has shown remarkable success in treating certain types of blood cancers, such as leukemia and lymphoma, and is being explored for solid tumors. CAR T-cell therapy offers a promising personalized treatment, with ongoing research aimed at enhancing its safety, effectiveness, and applicability to a wider range of cancers.